Imatinib-d3 – 500 µg

Brand:
Cayman
CAS:
1134803-18-1
Storage:
-20
UN-No:
Non-Hazardous - /

Imatinib-d3 is intended for use as an internal standard for the quantification of imatinib (Item No. 13139) by GC- or LC-MS. Imatinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit.{47196} It inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC50s = ~0.3 and ~0.1 μM, respectively).{47196,47197} Imatinib inhibits the proliferation of Bcr-Abl-dependent R10(–) cells (IC50s = ~35-40 nM) and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner.{47196, 20180} It prolongs survival in a mouse model of chronic myeloid leukemia when administered at a dose of 100 mg/kg twice per day.{20177} Imatinib (25 and 50 µM) also inhibits the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome CoV (SARS-CoV) in Vero E6 cells.{57353} It reduces viral titers in Vero cells infected with infectious bronchitis virus (IBV), a coronavirus, when used at a concentration of 10 µM via inhibition of IBV surface glycoprotein protein-induced syncytia formation and virus-cell fusion.{45828} Formulations containing imatinib have been used in the treatment of various cancers.  

 

Available on backorder

SKU: - Category:

Description

An internal standard for the quantification of imatinib by GC- or LC-MS


Formal name: 4-​[[4-​(methyl-​d3)​-​1-​piperazinyl]​methyl]​-​N-​[4-​methyl-​3-​[[4-​(3-​pyridinyl)​-​2-​pyrimidinyl]​amino]​phenyl]-benzamide

Synonyms:  Genfatinib-d3

Molecular weight: 496.6

CAS: 1134803-18-1

Purity: ≥99% deuterated forms (d1-d3)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Antivirals|Entry/fusion Inhibitors||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Immunology & Inflammation|Pulmonary Diseases|MERS||Research Area|Immunology & Inflammation|Pulmonary Diseases|SARS||Research Area|Infectious Disease|Viral Diseases|Coronaviruses